20-F/A: BioNTech SE Files Amended Annual Report for Fiscal Year 2025

BioNTech SE has filed an amendment to its 2025 annual report, primarily to correct a typographical error in the auditor's opinion date and to include updated share count information.

Summary

• BioNTech SE filed an amendment (Amendment No. 2) to its Form 20-F for the fiscal year ended December 31, 2025.
• The amendment corrects a typographical error in the date of the audit opinions from EY GmbH & Co. KG Wirtschaftsprfungsgesellschaft.
• It also includes an updated count of outstanding shares as of the most recent practicable date.
• No changes were made to the financial statements or the substance of the audit opinions themselves, other than the date correction.
• The filing also includes updated certifications from the Principal Executive Officer and Principal Financial Officer.
• The company's total revenues for 2025 were €2,869.9 million, a slight increase from €2,751.1 million in 2024, but a decrease from €3,819.0 million in 2023.
• The company reported a net loss of €1,136.1 million for 2025, compared to a net loss of €665.3 million in 2024 and a net profit of €930.3 million in 2023.
• Key acquisitions in 2025 included Biotheus for €280.1 million and CureVac N.V. for €400.9 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss and operating loss, despite strategic acquisitions and positive revenue from out-licensing. The ongoing litigation also presents significant risk.

Positives

• The company completed significant acquisitions in 2025, including Biotheus and CureVac N.V., expanding its capabilities and pipeline.
• Revenues from out-licensing increased significantly, with €613.0 million recognized from the Bristol Myers Squibb collaboration.
• The company's finance result remained positive, although it decreased to €354.1 million in 2025 from €636.6 million in 2024.
• Despite a net loss, the company's cash and cash equivalents remained substantial at €7,675.4 million as of December 31, 2025.

Negatives

• The company reported a net loss of €1,136.1 million for the year ended December 31, 2025, a significant increase from the €665.3 million loss in 2024.
• Operating profit/loss was negative at €1,404.9 million in 2025, an increase in loss from €1,314.3 million in 2024.
• Research and development expenses were €2,104.9 million in 2025, an increase from €2,254.2 million in 2024, but still a significant cost.
• Other operating expenses increased substantially to €1,088.3 million in 2025 from €811.5 million in 2024, largely due to contractual disputes and settlements.

Risks

• The company is involved in multiple patent infringement lawsuits with Moderna, GlaxoSmithKline, Arbutus, Genevant, Promosome, and CureVac, which could result in significant financial liabilities and operational disruptions.
• The company's financial performance is heavily reliant on the success of its COVID-19 vaccine revenues, which are subject to market demand fluctuations.
• Significant R&D expenses and potential impairments on intangible assets and property, plant, and equipment pose financial risks.
• The company faces risks related to the integration of acquired businesses, Biotheus and CureVac N.V., which could impact future financial performance.
• The company's future outlook is subject to the success of its pipeline candidates and the ability to navigate complex regulatory environments.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the financial results for the year ended December 31, 2025. However, the company's strategy includes a strong drive to build out its global development organization, diversify its therapeutic area footprint, and enhance capabilities through complementary acquisitions, technologies, infrastructure, and manufacturing.

Management Comments

• The company's management believes it has strong defenses against patent infringement allegations and intends to vigorously defend itself.
• Management's assessment of contingent liabilities is based on estimates and assumptions that may prove to be inaccurate, and unanticipated events could lead to changes in these estimates.
• The company's management is analyzing the effects of implementing IFRS 18, which will introduce new presentation and disclosure requirements.

Industry Context

StockSavvy.ai notes that BioNTech's filing reflects the ongoing challenges and opportunities in the biotechnology sector, particularly in the post-pandemic landscape. The significant R&D investments, strategic acquisitions, and ongoing patent litigation are characteristic of companies in this dynamic industry.

Management Changes

Legal Proceedings

• Moderna is pursuing patent infringement lawsuits against BioNTech and Pfizer in Germany, the UK, and the United States related to Comirnaty.
• Arbutus and Genevant have filed a lawsuit alleging infringement of lipid nanoparticle technology patents.
• GlaxoSmithKline has filed lawsuits alleging infringement of patents related to the cationic lipid used in Comirnaty in the US, Ireland, and the Unified Patent Court.
• Promosome LLC has filed a lawsuit alleging infringement of a patent in the Unified Patent Court.
• CureVac AG had filed lawsuits alleging infringement of patents and utility models related to Comirnaty, but these claims were withdrawn by CureVac after BioNTech's acquisition of CureVac.
• BioNTech has filed a lawsuit against Moderna alleging infringement of a U.S. patent related to mRNA technology.

Related Party Transactions

• Purchases of various goods and services from entities controlled by ATHOS KG amounted to €1.4 million in 2025.

Stakeholder Impact

• Shareholders may be impacted by the increased net loss and ongoing litigation, which could affect share price.
• Employees may be affected by restructuring due to pipeline prioritization and management changes.
• Customers (e.g., European Commission, German government, Pfizer, Bristol Myers Squibb) are involved in ongoing collaborations and supply agreements.

Next Steps

• The company will continue to monitor the status of ongoing litigation and claims.
• The company is analyzing the effects of implementing IFRS 18.
• The company plans to advance next-generation mRNA innovations through a new, independent company led by its co-founders.
• An executive search is underway to identify successors for the CEO and CMO roles.

Key Dates

Recommendation

While BioNTech has made strategic acquisitions and has strong revenue from out-licensing, the significant increase in net loss and operating loss, coupled with extensive ongoing patent litigation, warrants a cautious 'hold' rating. The company's future performance is contingent on the successful development of its pipeline and the resolution of legal challenges.

Keywords

BioNTech SE, Form 20-F/A, Annual Report, Financial Statements, Audit Opinion, Acquisitions, Biotheus, CureVac